

# Global Monoclonal Antibody Drugs for Cancer Market Research Report 2024, Forecast to 2032

<https://marketpublishers.com/r/GC755DCF791EEN.html>

Date: October 2024

Pages: 151

Price: US\$ 3,400.00 (Single User License)

ID: GC755DCF791EEN

## Abstracts

### Report Overview

Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing.

The global Monoclonal Antibody Drugs for Cancer market size was estimated at USD 87150 million in 2023 and is projected to reach USD 181608.02 million by 2032, exhibiting a CAGR of 8.50% during the forecast period.

North America Monoclonal Antibody Drugs for Cancer market size was estimated at USD 26138.34 million in 2023, at a CAGR of 7.29% during the forecast period of 2024 through 2032.

This report provides a deep insight into the global Monoclonal Antibody Drugs for Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Monoclonal Antibody Drugs for Cancer Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the

main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Monoclonal Antibody Drugs for Cancer market in any manner.

### Global Monoclonal Antibody Drugs for Cancer Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

#### Key Company

Johnson & Johnson

Novartis

Gilead Sciences

Roche

Bristol-Myers Squibb

Amgen

AstraZeneca

Merck & Co

Takeda

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer

Regeneron

Innovent

Hengrui Medicine

Market Segmentation (by Type)

Mouse-derived Antibodies

Chimeric Antibodies

Humanized Antibodies

Market Segmentation (by Application)

Lung Cancer

Breast Cancer

Prostate Cancer

Blood-related Cancer

Other

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

#### Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Monoclonal Antibody Drugs for Cancer Market

Overview of the regional outlook of the Monoclonal Antibody Drugs for Cancer Market:

#### Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your

marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

## Customization of the Report

In case of any queries or customization requirements, please connect with our sales

team, who will ensure that your requirements are met.

## Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Monoclonal Antibody Drugs for Cancer Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Monoclonal Antibody Drugs for Cancer, their output value, profit level, regional supply, production capacity layout, etc.

from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.

Chapter 13 is the main points and conclusions of the report.

## Contents

### **1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE**

- 1.1 Market Definition and Statistical Scope of Monoclonal Antibody Drugs for Cancer
- 1.2 Key Market Segments
  - 1.2.1 Monoclonal Antibody Drugs for Cancer Segment by Type
  - 1.2.2 Monoclonal Antibody Drugs for Cancer Segment by Application
- 1.3 Methodology & Sources of Information
  - 1.3.1 Research Methodology
  - 1.3.2 Research Process
  - 1.3.3 Market Breakdown and Data Triangulation
  - 1.3.4 Base Year
  - 1.3.5 Report Assumptions & Caveats

### **2 MONOCLONAL ANTIBODY DRUGS FOR CANCER MARKET OVERVIEW**

- 2.1 Global Market Overview
  - 2.1.1 Global Monoclonal Antibody Drugs for Cancer Market Size (M USD) Estimates and Forecasts (2019-2032)
  - 2.1.2 Global Monoclonal Antibody Drugs for Cancer Sales Estimates and Forecasts (2019-2032)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

### **3 MONOCLONAL ANTIBODY DRUGS FOR CANCER MARKET COMPETITIVE LANDSCAPE**

- 3.1 Global Monoclonal Antibody Drugs for Cancer Sales by Manufacturers (2019-2024)
- 3.2 Global Monoclonal Antibody Drugs for Cancer Revenue Market Share by Manufacturers (2019-2024)
- 3.3 Monoclonal Antibody Drugs for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4 Global Monoclonal Antibody Drugs for Cancer Average Price by Manufacturers (2019-2024)
- 3.5 Manufacturers Monoclonal Antibody Drugs for Cancer Sales Sites, Area Served, Product Type
- 3.6 Monoclonal Antibody Drugs for Cancer Market Competitive Situation and Trends
  - 3.6.1 Monoclonal Antibody Drugs for Cancer Market Concentration Rate

3.6.2 Global 5 and 10 Largest Monoclonal Antibody Drugs for Cancer Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

## **4 MONOCLONAL ANTIBODY DRUGS FOR CANCER INDUSTRY CHAIN ANALYSIS**

4.1 Monoclonal Antibody Drugs for Cancer Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

## **5 THE DEVELOPMENT AND DYNAMICS OF MONOCLONAL ANTIBODY DRUGS FOR CANCER MARKET**

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

## **6 MONOCLONAL ANTIBODY DRUGS FOR CANCER MARKET SEGMENTATION BY TYPE**

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Monoclonal Antibody Drugs for Cancer Sales Market Share by Type (2019-2024)

6.3 Global Monoclonal Antibody Drugs for Cancer Market Size Market Share by Type (2019-2024)

6.4 Global Monoclonal Antibody Drugs for Cancer Price by Type (2019-2024)

## **7 MONOCLONAL ANTIBODY DRUGS FOR CANCER MARKET SEGMENTATION BY APPLICATION**

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Monoclonal Antibody Drugs for Cancer Market Sales by Application  
(2019-2024)

7.3 Global Monoclonal Antibody Drugs for Cancer Market Size (M USD) by Application  
(2019-2024)

7.4 Global Monoclonal Antibody Drugs for Cancer Sales Growth Rate by Application  
(2019-2024)

## **8 MONOCLONAL ANTIBODY DRUGS FOR CANCER MARKET CONSUMPTION BY REGION**

8.1 Global Monoclonal Antibody Drugs for Cancer Sales by Region

8.1.1 Global Monoclonal Antibody Drugs for Cancer Sales by Region

8.1.2 Global Monoclonal Antibody Drugs for Cancer Sales Market Share by Region

8.2 North America

8.2.1 North America Monoclonal Antibody Drugs for Cancer Sales by Country

8.2.2 U.S.

8.2.3 Canada

8.2.4 Mexico

8.3 Europe

8.3.1 Europe Monoclonal Antibody Drugs for Cancer Sales by Country

8.3.2 Germany

8.3.3 France

8.3.4 U.K.

8.3.5 Italy

8.3.6 Russia

8.4 Asia Pacific

8.4.1 Asia Pacific Monoclonal Antibody Drugs for Cancer Sales by Region

8.4.2 China

8.4.3 Japan

8.4.4 South Korea

8.4.5 India

8.4.6 Southeast Asia

8.5 South America

8.5.1 South America Monoclonal Antibody Drugs for Cancer Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Monoclonal Antibody Drugs for Cancer Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

## **9 MONOCLONAL ANTIBODY DRUGS FOR CANCER MARKET PRODUCTION BY REGION**

9.1 Global Production of Monoclonal Antibody Drugs for Cancer by Region (2019-2024)

9.2 Global Monoclonal Antibody Drugs for Cancer Revenue Market Share by Region (2019-2024)

9.3 Global Monoclonal Antibody Drugs for Cancer Production, Revenue, Price and Gross Margin (2019-2024)

9.4 North America Monoclonal Antibody Drugs for Cancer Production

9.4.1 North America Monoclonal Antibody Drugs for Cancer Production Growth Rate (2019-2024)

9.4.2 North America Monoclonal Antibody Drugs for Cancer Production, Revenue, Price and Gross Margin (2019-2024)

9.5 Europe Monoclonal Antibody Drugs for Cancer Production

9.5.1 Europe Monoclonal Antibody Drugs for Cancer Production Growth Rate (2019-2024)

9.5.2 Europe Monoclonal Antibody Drugs for Cancer Production, Revenue, Price and Gross Margin (2019-2024)

9.6 Japan Monoclonal Antibody Drugs for Cancer Production (2019-2024)

9.6.1 Japan Monoclonal Antibody Drugs for Cancer Production Growth Rate (2019-2024)

9.6.2 Japan Monoclonal Antibody Drugs for Cancer Production, Revenue, Price and Gross Margin (2019-2024)

9.7 China Monoclonal Antibody Drugs for Cancer Production (2019-2024)

9.7.1 China Monoclonal Antibody Drugs for Cancer Production Growth Rate (2019-2024)

9.7.2 China Monoclonal Antibody Drugs for Cancer Production, Revenue, Price and Gross Margin (2019-2024)

## **10 KEY COMPANIES PROFILE**

10.1 Johnson and Johnson

10.1.1 Johnson and Johnson Monoclonal Antibody Drugs for Cancer Basic Information

- 10.1.2 Johnson and Johnson Monoclonal Antibody Drugs for Cancer Product Overview
- 10.1.3 Johnson and Johnson Monoclonal Antibody Drugs for Cancer Product Market Performance
- 10.1.4 Johnson and Johnson Business Overview
- 10.1.5 Johnson and Johnson Monoclonal Antibody Drugs for Cancer SWOT Analysis
- 10.1.6 Johnson and Johnson Recent Developments
- 10.2 Novartis
  - 10.2.1 Novartis Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.2.2 Novartis Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.2.3 Novartis Monoclonal Antibody Drugs for Cancer Product Market Performance
  - 10.2.4 Novartis Business Overview
  - 10.2.5 Novartis Monoclonal Antibody Drugs for Cancer SWOT Analysis
  - 10.2.6 Novartis Recent Developments
- 10.3 Gilead Sciences
  - 10.3.1 Gilead Sciences Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.3.2 Gilead Sciences Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.3.3 Gilead Sciences Monoclonal Antibody Drugs for Cancer Product Market Performance
  - 10.3.4 Gilead Sciences Monoclonal Antibody Drugs for Cancer SWOT Analysis
  - 10.3.5 Gilead Sciences Business Overview
  - 10.3.6 Gilead Sciences Recent Developments
- 10.4 Roche
  - 10.4.1 Roche Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.4.2 Roche Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.4.3 Roche Monoclonal Antibody Drugs for Cancer Product Market Performance
  - 10.4.4 Roche Business Overview
  - 10.4.5 Roche Recent Developments
- 10.5 Bristol-Myers Squibb
  - 10.5.1 Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.5.2 Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.5.3 Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Product Market Performance
  - 10.5.4 Bristol-Myers Squibb Business Overview
  - 10.5.5 Bristol-Myers Squibb Recent Developments
- 10.6 Amgen
  - 10.6.1 Amgen Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.6.2 Amgen Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.6.3 Amgen Monoclonal Antibody Drugs for Cancer Product Market Performance

- 10.6.4 Amgen Business Overview
- 10.6.5 Amgen Recent Developments
- 10.7 AstraZeneca
  - 10.7.1 AstraZeneca Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.7.2 AstraZeneca Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.7.3 AstraZeneca Monoclonal Antibody Drugs for Cancer Product Market Performance
  - 10.7.4 AstraZeneca Business Overview
  - 10.7.5 AstraZeneca Recent Developments
- 10.8 Merck and Co
  - 10.8.1 Merck and Co Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.8.2 Merck and Co Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.8.3 Merck and Co Monoclonal Antibody Drugs for Cancer Product Market Performance
  - 10.8.4 Merck and Co Business Overview
  - 10.8.5 Merck and Co Recent Developments
- 10.9 Takeda
  - 10.9.1 Takeda Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.9.2 Takeda Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.9.3 Takeda Monoclonal Antibody Drugs for Cancer Product Market Performance
  - 10.9.4 Takeda Business Overview
  - 10.9.5 Takeda Recent Developments
- 10.10 Merck KGaA
  - 10.10.1 Merck KGaA Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.10.2 Merck KGaA Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.10.3 Merck KGaA Monoclonal Antibody Drugs for Cancer Product Market Performance
  - 10.10.4 Merck KGaA Business Overview
  - 10.10.5 Merck KGaA Recent Developments
- 10.11 Seagen
  - 10.11.1 Seagen Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.11.2 Seagen Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.11.3 Seagen Monoclonal Antibody Drugs for Cancer Product Market Performance
  - 10.11.4 Seagen Business Overview
  - 10.11.5 Seagen Recent Developments
- 10.12 Eli Lilly
  - 10.12.1 Eli Lilly Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.12.2 Eli Lilly Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.12.3 Eli Lilly Monoclonal Antibody Drugs for Cancer Product Market Performance

- 10.12.4 Eli Lilly Business Overview
- 10.12.5 Eli Lilly Recent Developments
- 10.13 Ono Pharmaceutical
  - 10.13.1 Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.13.2 Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.13.3 Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Product Market Performance
  - 10.13.4 Ono Pharmaceutical Business Overview
  - 10.13.5 Ono Pharmaceutical Recent Developments
- 10.14 Pfizer
  - 10.14.1 Pfizer Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.14.2 Pfizer Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.14.3 Pfizer Monoclonal Antibody Drugs for Cancer Product Market Performance
  - 10.14.4 Pfizer Business Overview
  - 10.14.5 Pfizer Recent Developments
- 10.15 Regeneron
  - 10.15.1 Regeneron Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.15.2 Regeneron Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.15.3 Regeneron Monoclonal Antibody Drugs for Cancer Product Market Performance
  - 10.15.4 Regeneron Business Overview
  - 10.15.5 Regeneron Recent Developments
- 10.16 Innovent
  - 10.16.1 Innovent Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.16.2 Innovent Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.16.3 Innovent Monoclonal Antibody Drugs for Cancer Product Market Performance
  - 10.16.4 Innovent Business Overview
  - 10.16.5 Innovent Recent Developments
- 10.17 Hengrui Medicine
  - 10.17.1 Hengrui Medicine Monoclonal Antibody Drugs for Cancer Basic Information
  - 10.17.2 Hengrui Medicine Monoclonal Antibody Drugs for Cancer Product Overview
  - 10.17.3 Hengrui Medicine Monoclonal Antibody Drugs for Cancer Product Market Performance
  - 10.17.4 Hengrui Medicine Business Overview
  - 10.17.5 Hengrui Medicine Recent Developments

## **11 MONOCLONAL ANTIBODY DRUGS FOR CANCER MARKET FORECAST BY REGION**

11.1 Global Monoclonal Antibody Drugs for Cancer Market Size Forecast

11.2 Global Monoclonal Antibody Drugs for Cancer Market Forecast by Region

11.2.1 North America Market Size Forecast by Country

11.2.2 Europe Monoclonal Antibody Drugs for Cancer Market Size Forecast by Country

11.2.3 Asia Pacific Monoclonal Antibody Drugs for Cancer Market Size Forecast by Region

11.2.4 South America Monoclonal Antibody Drugs for Cancer Market Size Forecast by Country

11.2.5 Middle East and Africa Forecasted Consumption of Monoclonal Antibody Drugs for Cancer by Country

## **12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)**

12.1 Global Monoclonal Antibody Drugs for Cancer Market Forecast by Type (2025-2032)

12.1.1 Global Forecasted Sales of Monoclonal Antibody Drugs for Cancer by Type (2025-2032)

12.1.2 Global Monoclonal Antibody Drugs for Cancer Market Size Forecast by Type (2025-2032)

12.1.3 Global Forecasted Price of Monoclonal Antibody Drugs for Cancer by Type (2025-2032)

12.2 Global Monoclonal Antibody Drugs for Cancer Market Forecast by Application (2025-2032)

12.2.1 Global Monoclonal Antibody Drugs for Cancer Sales (K MT) Forecast by Application

12.2.2 Global Monoclonal Antibody Drugs for Cancer Market Size (M USD) Forecast by Application (2025-2032)

## **13 CONCLUSION AND KEY FINDINGS**

## List Of Tables

### LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Monoclonal Antibody Drugs for Cancer Market Size Comparison by Region (M USD)

Table 5. Global Monoclonal Antibody Drugs for Cancer Sales (K MT) by Manufacturers (2019-2024)

Table 6. Global Monoclonal Antibody Drugs for Cancer Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Monoclonal Antibody Drugs for Cancer Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Monoclonal Antibody Drugs for Cancer Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody Drugs for Cancer as of 2022)

Table 10. Global Market Monoclonal Antibody Drugs for Cancer Average Price (USD/MT) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Monoclonal Antibody Drugs for Cancer Sales Sites and Area Served

Table 12. Manufacturers Monoclonal Antibody Drugs for Cancer Product Type

Table 13. Global Monoclonal Antibody Drugs for Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Monoclonal Antibody Drugs for Cancer

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Monoclonal Antibody Drugs for Cancer Market Challenges

Table 22. Global Monoclonal Antibody Drugs for Cancer Sales by Type (K MT)

Table 23. Global Monoclonal Antibody Drugs for Cancer Market Size by Type (M USD)

Table 24. Global Monoclonal Antibody Drugs for Cancer Sales (K MT) by Type (2019-2024)

Table 25. Global Monoclonal Antibody Drugs for Cancer Sales Market Share by Type

(2019-2024)

Table 26. Global Monoclonal Antibody Drugs for Cancer Market Size (M USD) by Type (2019-2024)

Table 27. Global Monoclonal Antibody Drugs for Cancer Market Size Share by Type (2019-2024)

Table 28. Global Monoclonal Antibody Drugs for Cancer Price (USD/MT) by Type (2019-2024)

Table 29. Global Monoclonal Antibody Drugs for Cancer Sales (K MT) by Application

Table 30. Global Monoclonal Antibody Drugs for Cancer Market Size by Application

Table 31. Global Monoclonal Antibody Drugs for Cancer Sales by Application (2019-2024) & (K MT)

Table 32. Global Monoclonal Antibody Drugs for Cancer Sales Market Share by Application (2019-2024)

Table 33. Global Monoclonal Antibody Drugs for Cancer Sales by Application (2019-2024) & (M USD)

Table 34. Global Monoclonal Antibody Drugs for Cancer Market Share by Application (2019-2024)

Table 35. Global Monoclonal Antibody Drugs for Cancer Sales Growth Rate by Application (2019-2024)

Table 36. Global Monoclonal Antibody Drugs for Cancer Sales by Region (2019-2024) & (K MT)

Table 37. Global Monoclonal Antibody Drugs for Cancer Sales Market Share by Region (2019-2024)

Table 38. North America Monoclonal Antibody Drugs for Cancer Sales by Country (2019-2024) & (K MT)

Table 39. Europe Monoclonal Antibody Drugs for Cancer Sales by Country (2019-2024) & (K MT)

Table 40. Asia Pacific Monoclonal Antibody Drugs for Cancer Sales by Region (2019-2024) & (K MT)

Table 41. South America Monoclonal Antibody Drugs for Cancer Sales by Country (2019-2024) & (K MT)

Table 42. Middle East and Africa Monoclonal Antibody Drugs for Cancer Sales by Region (2019-2024) & (K MT)

Table 43. Global Monoclonal Antibody Drugs for Cancer Production (K MT) by Region (2019-2024)

Table 44. Global Monoclonal Antibody Drugs for Cancer Revenue (US\$ Million) by Region (2019-2024)

Table 45. Global Monoclonal Antibody Drugs for Cancer Revenue Market Share by Region (2019-2024)

Table 46. Global Monoclonal Antibody Drugs for Cancer Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 47. North America Monoclonal Antibody Drugs for Cancer Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 48. Europe Monoclonal Antibody Drugs for Cancer Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 49. Japan Monoclonal Antibody Drugs for Cancer Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 50. China Monoclonal Antibody Drugs for Cancer Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 51. Johnson and Johnson Monoclonal Antibody Drugs for Cancer Basic Information

Table 52. Johnson and Johnson Monoclonal Antibody Drugs for Cancer Product Overview

Table 53. Johnson and Johnson Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 54. Johnson and Johnson Business Overview

Table 55. Johnson and Johnson Monoclonal Antibody Drugs for Cancer SWOT Analysis

Table 56. Johnson and Johnson Recent Developments

Table 57. Novartis Monoclonal Antibody Drugs for Cancer Basic Information

Table 58. Novartis Monoclonal Antibody Drugs for Cancer Product Overview

Table 59. Novartis Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 60. Novartis Business Overview

Table 61. Novartis Monoclonal Antibody Drugs for Cancer SWOT Analysis

Table 62. Novartis Recent Developments

Table 63. Gilead Sciences Monoclonal Antibody Drugs for Cancer Basic Information

Table 64. Gilead Sciences Monoclonal Antibody Drugs for Cancer Product Overview

Table 65. Gilead Sciences Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 66. Gilead Sciences Monoclonal Antibody Drugs for Cancer SWOT Analysis

Table 67. Gilead Sciences Business Overview

Table 68. Gilead Sciences Recent Developments

Table 69. Roche Monoclonal Antibody Drugs for Cancer Basic Information

Table 70. Roche Monoclonal Antibody Drugs for Cancer Product Overview

Table 71. Roche Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 72. Roche Business Overview

Table 73. Roche Recent Developments

- Table 74. Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Basic Information
- Table 75. Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Product Overview
- Table 76. Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 77. Bristol-Myers Squibb Business Overview
- Table 78. Bristol-Myers Squibb Recent Developments
- Table 79. Amgen Monoclonal Antibody Drugs for Cancer Basic Information
- Table 80. Amgen Monoclonal Antibody Drugs for Cancer Product Overview
- Table 81. Amgen Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 82. Amgen Business Overview
- Table 83. Amgen Recent Developments
- Table 84. AstraZeneca Monoclonal Antibody Drugs for Cancer Basic Information
- Table 85. AstraZeneca Monoclonal Antibody Drugs for Cancer Product Overview
- Table 86. AstraZeneca Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 87. AstraZeneca Business Overview
- Table 88. AstraZeneca Recent Developments
- Table 89. Merck and Co Monoclonal Antibody Drugs for Cancer Basic Information
- Table 90. Merck and Co Monoclonal Antibody Drugs for Cancer Product Overview
- Table 91. Merck and Co Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 92. Merck and Co Business Overview
- Table 93. Merck and Co Recent Developments
- Table 94. Takeda Monoclonal Antibody Drugs for Cancer Basic Information
- Table 95. Takeda Monoclonal Antibody Drugs for Cancer Product Overview
- Table 96. Takeda Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 97. Takeda Business Overview
- Table 98. Takeda Recent Developments
- Table 99. Merck KGaA Monoclonal Antibody Drugs for Cancer Basic Information
- Table 100. Merck KGaA Monoclonal Antibody Drugs for Cancer Product Overview
- Table 101. Merck KGaA Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 102. Merck KGaA Business Overview
- Table 103. Merck KGaA Recent Developments
- Table 104. Seagen Monoclonal Antibody Drugs for Cancer Basic Information

- Table 105. Seagen Monoclonal Antibody Drugs for Cancer Product Overview
- Table 106. Seagen Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 107. Seagen Business Overview
- Table 108. Seagen Recent Developments
- Table 109. Eli Lilly Monoclonal Antibody Drugs for Cancer Basic Information
- Table 110. Eli Lilly Monoclonal Antibody Drugs for Cancer Product Overview
- Table 111. Eli Lilly Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 112. Eli Lilly Business Overview
- Table 113. Eli Lilly Recent Developments
- Table 114. Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Basic Information
- Table 115. Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Product Overview
- Table 116. Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 117. Ono Pharmaceutical Business Overview
- Table 118. Ono Pharmaceutical Recent Developments
- Table 119. Pfizer Monoclonal Antibody Drugs for Cancer Basic Information
- Table 120. Pfizer Monoclonal Antibody Drugs for Cancer Product Overview
- Table 121. Pfizer Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 122. Pfizer Business Overview
- Table 123. Pfizer Recent Developments
- Table 124. Regeneron Monoclonal Antibody Drugs for Cancer Basic Information
- Table 125. Regeneron Monoclonal Antibody Drugs for Cancer Product Overview
- Table 126. Regeneron Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 127. Regeneron Business Overview
- Table 128. Regeneron Recent Developments
- Table 129. Innovent Monoclonal Antibody Drugs for Cancer Basic Information
- Table 130. Innovent Monoclonal Antibody Drugs for Cancer Product Overview
- Table 131. Innovent Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 132. Innovent Business Overview
- Table 133. Innovent Recent Developments
- Table 134. Hengrui Medicine Monoclonal Antibody Drugs for Cancer Basic Information
- Table 135. Hengrui Medicine Monoclonal Antibody Drugs for Cancer Product Overview

Table 136. Hengrui Medicine Monoclonal Antibody Drugs for Cancer Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 137. Hengrui Medicine Business Overview

Table 138. Hengrui Medicine Recent Developments

Table 139. Global Monoclonal Antibody Drugs for Cancer Sales Forecast by Region (2025-2032) & (K MT)

Table 140. Global Monoclonal Antibody Drugs for Cancer Market Size Forecast by Region (2025-2032) & (M USD)

Table 141. North America Monoclonal Antibody Drugs for Cancer Sales Forecast by Country (2025-2032) & (K MT)

Table 142. North America Monoclonal Antibody Drugs for Cancer Market Size Forecast by Country (2025-2032) & (M USD)

Table 143. Europe Monoclonal Antibody Drugs for Cancer Sales Forecast by Country (2025-2032) & (K MT)

Table 144. Europe Monoclonal Antibody Drugs for Cancer Market Size Forecast by Country (2025-2032) & (M USD)

Table 145. Asia Pacific Monoclonal Antibody Drugs for Cancer Sales Forecast by Region (2025-2032) & (K MT)

Table 146. Asia Pacific Monoclonal Antibody Drugs for Cancer Market Size Forecast by Region (2025-2032) & (M USD)

Table 147. South America Monoclonal Antibody Drugs for Cancer Sales Forecast by Country (2025-2032) & (K MT)

Table 148. South America Monoclonal Antibody Drugs for Cancer Market Size Forecast by Country (2025-2032) & (M USD)

Table 149. Middle East and Africa Monoclonal Antibody Drugs for Cancer Consumption Forecast by Country (2025-2032) & (Units)

Table 150. Middle East and Africa Monoclonal Antibody Drugs for Cancer Market Size Forecast by Country (2025-2032) & (M USD)

Table 151. Global Monoclonal Antibody Drugs for Cancer Sales Forecast by Type (2025-2032) & (K MT)

Table 152. Global Monoclonal Antibody Drugs for Cancer Market Size Forecast by Type (2025-2032) & (M USD)

Table 153. Global Monoclonal Antibody Drugs for Cancer Price Forecast by Type (2025-2032) & (USD/MT)

Table 154. Global Monoclonal Antibody Drugs for Cancer Sales (K MT) Forecast by Application (2025-2032)

Table 155. Global Monoclonal Antibody Drugs for Cancer Market Size Forecast by Application (2025-2032) & (M USD)

## List Of Figures

### LIST OF FIGURES

- Figure 1. Product Picture of Monoclonal Antibody Drugs for Cancer
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Monoclonal Antibody Drugs for Cancer Market Size (M USD), 2019-2032
- Figure 5. Global Monoclonal Antibody Drugs for Cancer Market Size (M USD) (2019-2032)
- Figure 6. Global Monoclonal Antibody Drugs for Cancer Sales (K MT) & (2019-2032)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Monoclonal Antibody Drugs for Cancer Market Size by Country (M USD)
- Figure 11. Monoclonal Antibody Drugs for Cancer Sales Share by Manufacturers in 2023
- Figure 12. Global Monoclonal Antibody Drugs for Cancer Revenue Share by Manufacturers in 2023
- Figure 13. Monoclonal Antibody Drugs for Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
- Figure 14. Global Market Monoclonal Antibody Drugs for Cancer Average Price (USD/MT) of Key Manufacturers in 2023
- Figure 15. The Global 5 and 10 Largest Players: Market Share by Monoclonal Antibody Drugs for Cancer Revenue in 2023
- Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 17. Global Monoclonal Antibody Drugs for Cancer Market Share by Type
- Figure 18. Sales Market Share of Monoclonal Antibody Drugs for Cancer by Type (2019-2024)
- Figure 19. Sales Market Share of Monoclonal Antibody Drugs for Cancer by Type in 2023
- Figure 20. Market Size Share of Monoclonal Antibody Drugs for Cancer by Type (2019-2024)
- Figure 21. Market Size Market Share of Monoclonal Antibody Drugs for Cancer by Type in 2023
- Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 23. Global Monoclonal Antibody Drugs for Cancer Market Share by Application
- Figure 24. Global Monoclonal Antibody Drugs for Cancer Sales Market Share by

Application (2019-2024)

Figure 25. Global Monoclonal Antibody Drugs for Cancer Sales Market Share by Application in 2023

Figure 26. Global Monoclonal Antibody Drugs for Cancer Market Share by Application (2019-2024)

Figure 27. Global Monoclonal Antibody Drugs for Cancer Market Share by Application in 2023

Figure 28. Global Monoclonal Antibody Drugs for Cancer Sales Growth Rate by Application (2019-2024)

Figure 29. Global Monoclonal Antibody Drugs for Cancer Sales Market Share by Region (2019-2024)

Figure 30. North America Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 31. North America Monoclonal Antibody Drugs for Cancer Sales Market Share by Country in 2023

Figure 32. U.S. Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 33. Canada Monoclonal Antibody Drugs for Cancer Sales (K MT) and Growth Rate (2019-2024)

Figure 34. Mexico Monoclonal Antibody Drugs for Cancer Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 36. Europe Monoclonal Antibody Drugs for Cancer Sales Market Share by Country in 2023

Figure 37. Germany Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 38. France Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 39. U.K. Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 40. Italy Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 41. Russia Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 42. Asia Pacific Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (K MT)

Figure 43. Asia Pacific Monoclonal Antibody Drugs for Cancer Sales Market Share by Region in 2023

Figure 44. China Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 45. Japan Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 46. South Korea Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 47. India Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 48. Southeast Asia Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 49. South America Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (K MT)

Figure 50. South America Monoclonal Antibody Drugs for Cancer Sales Market Share by Country in 2023

Figure 51. Brazil Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 52. Argentina Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 53. Columbia Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 54. Middle East and Africa Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (K MT)

Figure 55. Middle East and Africa Monoclonal Antibody Drugs for Cancer Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 57. UAE Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 58. Egypt Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 59. Nigeria Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 60. South Africa Monoclonal Antibody Drugs for Cancer Sales and Growth Rate (2019-2024) & (K MT)

Figure 61. Global Monoclonal Antibody Drugs for Cancer Production Market Share by Region (2019-2024)

Figure 62. North America Monoclonal Antibody Drugs for Cancer Production (K MT) Growth Rate (2019-2024)

Figure 63. Europe Monoclonal Antibody Drugs for Cancer Production (K MT) Growth

Rate (2019-2024)

Figure 64. Japan Monoclonal Antibody Drugs for Cancer Production (K MT) Growth Rate (2019-2024)

Figure 65. China Monoclonal Antibody Drugs for Cancer Production (K MT) Growth Rate (2019-2024)

Figure 66. Global Monoclonal Antibody Drugs for Cancer Sales Forecast by Volume (2019-2032) & (K MT)

Figure 67. Global Monoclonal Antibody Drugs for Cancer Market Size Forecast by Value (2019-2032) & (M USD)

Figure 68. Global Monoclonal Antibody Drugs for Cancer Sales Market Share Forecast by Type (2025-2032)

Figure 69. Global Monoclonal Antibody Drugs for Cancer Market Share Forecast by Type (2025-2032)

Figure 70. Global Monoclonal Antibody Drugs for Cancer Sales Forecast by Application (2025-2032)

Figure 71. Global Monoclonal Antibody Drugs for Cancer Market Share Forecast by Application (2025-2032)

## I would like to order

Product name: Global Monoclonal Antibody Drugs for Cancer Market Research Report 2024, Forecast to 2032

Product link: <https://marketpublishers.com/r/GC755DCF791EEN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC755DCF791EEN.html>